SWOG S0226 - for Metastatic Breast Cancer | Additional Fulvestrant and Anastrozole Improves PFS
Rita Sanghvi Mehta, MD, UC Irvine Health, talks about SWOG S0226 - for Metastatic Breast Cancer | Additional Fulvestrant and Anastrozole Improves PFS at MOASC 2018. Author: moasc Added: 08/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 14, 2018 Category: Cancer & Oncology Source Type: podcasts

Breast cancer: new advances in personalized medicine and therapeutics
Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, speaks to us about the different therapies being developed for the treatment of breast cancer. Dr Burris touches ... Author: VJOncology Added: 08/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 13, 2018 Category: Cancer & Oncology Source Type: podcasts

Sacituzumab govitecan for treatment-refractory metastatic breast cancer
Aditya Bardia, MD, MPH, of Massachusetts General Hospital, Boston, MA, discusses the promising efficacy data of sacituzumab govitecan, an anti-Trop-2/SN-38 antibody-drug conjugate (ADC), for treatment... Author: VJOncology Added: 08/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 3, 2018 Category: Cancer & Oncology Source Type: podcasts

Metastatic breast cancer: promising therapeutic avenues
The treatment landscape of metastatic breast cancer (mBC) is advancing rapidly. Here, Aditya Bardia, MD, MPH, of Massachusetts General Hospital, Boston, MA, discusses therapeutic developments and nove... Author: VJOncology Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts

Does Nab-Paclitaxel Improve Outcomes Compared to Paclitaxel in Second Line Treatment of Transitional Cell Carcinoma of the Bladder (or other cancers)? Highlights from ASCO 2018 (BMIC-048)
Dr. Daniel Goldstein reviews trial results comparing nab-paclitaxel to standard paclitaxel in second line treatment of bladder cancer, comparing these results to those in breast cancer and raising que... Author: BeaconMedIC Added: 07/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 31, 2018 Category: Cancer & Oncology Source Type: podcasts

The MONALEESA-3 study in HR+/HER2- advanced breast cancer
Douglas W. Blayney, MD, explains the significant improvement in PFS in the fulvestrant + ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer Author: obr Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts

the PERSEPHONE trial in early HER2+ breast cancer
Neelima Denduluri, MD, shares the results of the PERSEPHONE trial in early HER2+ breast cancer mean that 6 months of trastuzumab can be given rather than 12 months in the adjuvant setting Author: obr Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts

The MONALEESA-3 study in HR+/HER2- advanced breast cancer
Neelima Denduluri, MD, discusses the significance of the improvement in the PFS fulvestrant +ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer Author: obr Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts

MONALEESA-3 study in HR+/HER2- advanced breast cancer
Douglas W. Blayney, MD, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, on the significant improvement in PFS in the fulvestrant + ribociclib arm of the MONAL... Author: obr Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts

Early breast cancer treatment: denosumab
Exciting updates in the field of breast cancer were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. In this interview, Robert Coleman, MBBS, MD, FRCP, FR... Author: VJOncology Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts

PERSEPHONE: 6 vs. 12-month adjuvant trastuzumab in early breast cancer
Trastuzumab has revolutionized the treatment of HER2+ breast cancer; however, the benefit of a longer duration of this therapy is uncertain. The PERSEPHONE trial (ISRCTN52968807) looked at the efficac... Author: VJOncology Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts

Early breast cancer treatment: denosumab
Exciting updates in the field of breast cancer were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. In this interview, Robert Coleman, MBBS, MD, FRCP, FR... Author: VJOncology Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts

Outcomes of the MONARCH 2 study
Sara M. Tolaney, MD, MPH shares the MONARCH 2 study in pre and peri-menopausal ER+, HER2- breast cancer patients at ASCO 2018. Author: obr Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

Issue Summary: July 2018
David A. Bluemke, MD, PhD, Editor of Radiology discusses four research articles from the July 2018 issue of Radiology. ARTICLES DISCUSSED Summary of Outcome of Architectural Distortion Detected Only at Breast Tomosynthesis versus 2D Mammography Radiology 2018;288(1):38-46. Summary of Association between Screening Mammography Recall Rate and Interval Cancers in the UK Breast Cancer Service Screening Program: A Cohort Study. Radiology 2018;288(1):47-54. Summary of Comparative Effectiveness of Thermal Ablation, Surgical Resection, and Active Surveillance for T1a Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Resu...
Source: Radiology Podcasts - July 5, 2018 Category: Radiology Authors: The Radiological Society of North America Tags: Podcasts Source Type: podcasts

JAMA Oncology : Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Breast Cancer Screening
Interview with Nora Pashayan, BSc MSc MSt MD PhD FFPH, author of Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - July 5, 2018 Category: General Medicine Authors: The JAMA Network Source Type: podcasts

Use PARP-Inhibitors Early in Therapy for Metastatic Breast Cancer | Improve Response & Delay Toxic Therapy Use
Hope S. Rugo, MD, FASCO, University of California, San Francisco shares Use PARP-Inhibitors Early in Therapy for Metastatic Breast Cancer | Improve Response & Delay Toxic Therapy Use at ASCO 2018 Author: Annual-Meeting Added: 06/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 13, 2018 Category: Cancer & Oncology Source Type: podcasts

Lots of Therapies for Metastatic Breast Cancer | Clinical Trial Development is Key to Advancing Field
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Therapies for Metastatic Breast Cancer | Clinical Trial Development is Key to Advancing Field at ASCO 2018 Author: Annual-Meeting Added: 06/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Triple Negative Breast Cancer Immunotherapies | Pemborlizumab works in NeoAdjuvant Setting
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Triple Negative Breast Cancer Immunotherapies | Pemborlizumab works in NeoAdjuvant Setting at ASCO 2018 Author: Annual-Meeting Added: 06/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Metastatic Breast Cancer Does Well with Bria-IMT | Side-Effect Profile Not as Severe
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Metastatic Breast Cancer Does Well with Bria-IMT Side-Effect Profile Not as Severe at ASCO 2018 Author: Annual-Meeting Added: 06/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Talazoparib - Active in Metastatic Breast Cancer Pathologic Complete Response Rate of 53
Jennifer K. Litton, MD, MD Anderson Cancer Center, shares Talazoparib - Active in Metastatic Breast Cancer Pathologic Complete Response Rate of 53 at ASCO 2018 Author: Annual-Meeting Added: 06/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 8, 2018 Category: Cancer & Oncology Source Type: podcasts

JAMA Oncology : Outcomes of Multiple-Gene Sequencing After Diagnosis of Breast Cancer
Interview with Allison W. Kurian, M.D., M.Sc., author of Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - May 10, 2018 Category: General Medicine Authors: The JAMA Network Source Type: podcasts

Dr. Jame Abraham discusses the NSABP and breast cancer clincial trials
Dr. Jame Abraham, Director of the Breast Oncology program at Taussig Cancer Institute and Co-Director of the Cleveland Clinic Lerner College of Medicine, as he shares his experience and insight into ... Author: NSABP_Foundation Added: 04/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 20, 2018 Category: Cancer & Oncology Source Type: podcasts

Patients Should Still Test for BRCA Mutations They are in increased risk of breast cancer
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses how Patients Should Still Test for BRCA Mutations They are in increased risk of breast cancer. Author: Cancer-News Added: 04/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 10, 2018 Category: Cancer & Oncology Source Type: podcasts

Diabetes Core Update - April 2018
Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association’s four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 15 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a ...
Source: Diabetes Core Update - April 3, 2018 Category: Endocrinology Authors: American Diabetes Association Source Type: podcasts

Dr. Hurvitzs Study on Breast Cancer Using Tumor-Infiltrating Lymphocytes as a biomarker
Ashkan Lashkari, MD, shares Dr. Hurvitzs Study on Breast Cancer Using Tumor-Infiltrating Lymphocytes as a biomarker at the 2018 Oncology Summit in Huntington Beach, CA Author: moasc Added: 03/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Trials Evaluating Immunotherapies for Breast Cancer Either as single agent or with chemotherapy
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, examines Trials Evaluating Immunotherapies for Breast Cancer Either as single agent or with chemotherapy at the 201... Author: moasc Added: 03/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Immune Therapy Toxicities Related to Breast Cancer Thyroid and adrenal insufficiency
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, examines Immune Therapy Toxicities Related to Breast Cancer Thyroid and adrenal insufficiency at the 2018 Oncology ... Author: moasc Added: 03/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 9, 2018 Category: Cancer & Oncology Source Type: podcasts

Immune-Targeted Therapy in Breast Cancer Immune System Important for Long-Term Outcome
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, examines Immune-Targeted Therapy in Breast Cancer Immune System Important for Long-Term Outcome. at the 2018 Oncolog... Author: moasc Added: 03/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 9, 2018 Category: Cancer & Oncology Source Type: podcasts

The Role of Immunotherapy in Breast Cancer
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, examines The Role of Immunotherapy in Breast Cancer at the 2018 Oncology Summit in Huntington Beach, CA Author: moasc Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2018 Category: Cancer & Oncology Source Type: podcasts

Beyond APHINITY: What Now After Pivotal Breast Cancer Trial?
Dr Kathy Miller speaks with APHINITY's principal investigator about whether survival in HER2+ disease can be pushed even further. (Source: Medscape Oncology)
Source: Medscape Oncology - February 15, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Why Do Physicians Overtreat Elderly Breast Cancer Patients?
Drs Kathy Miller and Reshma Jagsi on the reasons behind practitioners'reluctance to omit radiation therapy in older patients. (Source: Medscape Oncology)
Source: Medscape Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Late Recurrence in ER- Positive Breast Cancer: Banking on Biomarkers
Evaluation of biomarkers after 5 years of standard therapy for hormone-positive breast cancer may help determine those at risk for recurrence and those who may need further endocrine therapy. (Source: Medscape Oncology)
Source: Medscape Oncology - January 17, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Neoadjuvent treatment for breast cancer - not living up to the promise
Neoadjuvant chemotherapy for breast cancer is a new strategy that was introduced towards the end of the 20th century with the aim of reducing tumour size - rendering an otherwise inoperable tumour operable, allowing more conservative surgery, and hopefully improving overall survival. Although data indicate that the first rationale remains valid,... (Source: The BMJ Podcast)
Source: The BMJ Podcast - January 11, 2018 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts

neoadjuvant treatment for breast cancer - not living up to the promise
Neoadjuvant chemotherapy for breast cancer is a new strategy that was introduced towards the end of the 20th century with the aim of reducing tumour size - rendering an otherwise inoperable tumour operable, allowing more conservative surgery, and hopefully improving overall survival. Although data indicate that the first rationale remains valid,... (Source: The BMJ Podcast)
Source: The BMJ Podcast - January 11, 2018 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts

Will Immunotherapy Be a PANACEA for Breast Cancer?
Drs Kathy Miller and Sherene Loi discuss advances in immunotherapy for breast cancer, particularly in HER2-positive disease and TNBC. (Source: Medscape Oncology)
Source: Medscape Oncology - January 2, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Takeaways From Dr. Kaklamani From SABCS 2017
What are the highlights from the 2017 San Antonio Breast Cancer Symposium (SABCS). Dr. Virginia Kaklamani, Professor Medicine at UT Health Science Center San Antonio and Leader of the Breast Cancer Pr... Author: patientpower Added: 12/30/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 30, 2017 Category: Cancer & Oncology Source Type: podcasts

For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go
Although the study didn't turn out as hoped, NSABP B-47 will help inform the decision of whether patients with low-level HER2 breast cancer should receive trastuzumab. (Source: Medscape Oncology)
Source: Medscape Oncology - December 29, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Does Breast Cancer Risk REACT to Celecoxib?
Does this COX-2 inhibitor alter breast cancer risk? Dr Kathy Miller discusses the results of the REACT trial with its primary investigator, Dr Charles Coombes. (Source: Medscape Oncology)
Source: Medscape Oncology - December 27, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Do Hormonal Contraceptives Increase Breast Cancer Risk?
Dr Andrew Kaunitz disputes the recent findings from a Danish breast cancer risk study that primarily studied women in a lower-risk group. (Source: Medscape ObGyn Podcast)
Source: Medscape ObGyn Podcast - December 22, 2017 Category: OBGYN Authors: Medscape Source Type: podcasts

Hormonal Contraception and Risk for Breast Cancer: Many Caveats
This large-scale study is an important contribution to the literature, notes Dr JoAnn Manson, but should it change practice? (Source: Medscape Medscape Podcast)
Source: Medscape Medscape Podcast - December 13, 2017 Category: General Medicine Authors: Medscape Source Type: podcasts

Deep Learning Algorithms for Detection of Lymph Node Metastases From Breast Cancer
Interview with Jeffrey Alan. Golden, MD, author of Deep Learning Algorithms for Detection of Lymph Node Metastases From Breast Cancer: Helping Artificial Intelligence Be Seen (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - December 12, 2017 Category: General Medicine Authors: The JAMA Network Source Type: podcasts

Levothyroxine and miscarriage, AI detection of breast cancer mets and DM retinopathy, hormone therapy for chronic disease prevention, and more
Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the December 12, 2017 issue (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - December 12, 2017 Category: General Medicine Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts

Genetic Mutations Responsible For Breast Cancer
Dr Pierfranco Conte, Professor of Oncology at the University of Padova and Director of the Division of Medical Oncology 2 at the Istituto Oncologico Veneto Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Is Genomic Profiling Useful For Breast Cancer Patients?
Dr Pierfranco Conte, Professor of Oncology at the University of Padova and Director of the Division of Medical Oncology 2 at the Istituto Oncologico Veneto Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Immunotherapy For Breast Cancer Patients: Where Do We Stand?
Dr Pierfranco Conte, Professor of Oncology at the University of Padova and Director of the Division of Medical Oncology 2 at the Istituto Oncologico Veneto Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Treatment Options For Breast Cancer Patients With Metastatic Disease
Dr Pierfranco Conte, Professor of Oncology at the University of Padova and Director of the Division of Medical Oncology 2 at the Istituto Oncologico Veneto Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Twitter Has Given Me Power To Learn And Connect
Joanne Taylor, secondary breast cancer patient and Advocate, speaks from ESMO 2017 Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

My Work To Get Metastatic Cancer Data Collected
Joanne Taylor, secondary breast cancer patient and Advocate, speaks from ESMO 2017 Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

How I Advocate For Breast Cancer Patients
Joanne Taylor, secondary breast cancer patient and Advocate, speaks from ESMO 2017 Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts